Retrogenix presents at NC3Rs workshop
Retrogenix has been invited to present at a meeting focusing on the preclinical analysis of cell-based cancer therapies, which takes place on Monday 19th November 2018 in London, UK.
The one-day workshop has been organised by the Cell and Gene Therapy Catapult in collaboration with the National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs).
Mark Aspinall-O’Dea will be presenting on target identification and in vitro safety screening of cell-based therapies, focusing particularly on techniques for screening CAR T cells for off-target binding prior to IND submission. Further details about the workshop can be found by visiting the NC3Rs website.
To find out more about our safety screening of cell therapies please see our applications page, or get in touch.